Bimatoprost

"Bimatoprost" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Descriptor ID	D000069580
MeSH Number(s)	D02.065.141 D10.251.355.255.550.775.500.175.250 D23.469.050.175.725.775.500.175.250 D23.469.700.670.175.250
Concept/Terms	Bimatoprost Bimatoprost Latisse Latisse Lumigan Lumigan AGN 192024 AGN 192024 192024, AGN

Below are MeSH descriptors whose meaning is more general than "Bimatoprost".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Amides [D02.065]
Bimatoprost [D02.065.141]
Lipids [D10]
Fatty Acids [D10.251]
Fatty Acids, Unsaturated [D10.251.355]
Eicosanoids [D10.251.355.255]
Prostaglandins [D10.251.355.255.550]
Prostaglandins, Synthetic [D10.251.355.255.550.775]
Prostaglandins F, Synthetic [D10.251.355.255.550.775.500]
Cloprostenol [D10.251.355.255.550.775.500.175]
Bimatoprost [D10.251.355.255.550.775.500.175.250]
Biological Factors [D23]
Inflammation Mediators [D23.469]
Autacoids [D23.469.050]
Eicosanoids [D23.469.050.175]
Prostaglandins [D23.469.050.175.725]
Prostaglandins, Synthetic [D23.469.050.175.725.775]
Prostaglandins F, Synthetic [D23.469.050.175.725.775.500]
Cloprostenol [D23.469.050.175.725.775.500.175]
Bimatoprost [D23.469.050.175.725.775.500.175.250]
Prostaglandins, Synthetic [D23.469.700]
Prostaglandins F, Synthetic [D23.469.700.670]
Cloprostenol [D23.469.700.670.175]
Bimatoprost [D23.469.700.670.175.250]

Below are MeSH descriptors whose meaning is related to "Bimatoprost".

Below are MeSH descriptors whose meaning is more specific than "Bimatoprost".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Bimatoprost" by people in this website by year, and whether "Bimatoprost" was a major or minor topic of these publications.

Bar chart showing 12 publications over 9 distinct years, with a maximum of 3 publications in 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	0	2	2
2009	0	1	1
2010	0	1	1
2011	0	1	1
2013	0	1	1
2015	0	1	1
2019	1	0	1
2020	1	0	1
2023	0	3	3

Below are the most recent publications written about "Bimatoprost" by people in Profiles.

Bowers ME, Wong MK, Ventimiglia J, Nicknam RM, Moster MR, Pro MJ, Dale E, Kolomeyer NN, Lee D, Zheng CX. Effect of bimatoprost sustained-release intracameral implant on intraocular pressure and medication burden in patients with prior glaucoma surgery. J Fr Ophtalmol. 2024 Feb; 47(2):103996.

View in: PubMed
Wong MK, Bowers ME, Ventimiglia J, Niknam RM, Moster MR, Pro MJ, Dale E, Kolomeyer NN, Lee D, Zheng CX. Short-Term Outcomes of Bimatoprost Sustained-Release Intracameral Implant in Glaucoma. J Glaucoma. 2023 09 01; 32(9):738-743.

View in: PubMed
Stamer WD, Perkumas KM, Kang MH, Dibas M, Robinson MR, Rhee DJ. Proposed Mechanism of Long-Term Intraocular Pressure Lowering With the Bimatoprost Implant. Invest Ophthalmol Vis Sci. 2023 03 01; 64(3):15.

View in: PubMed
Heo JY, Ooi YH, Rhee DJ. Effect of prostaglandin analogs: Latanoprost, bimatoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human trabecular meshwork endothelial cells. Exp Eye Res. 2020 05; 194:108019.

View in: PubMed
Brown GC, Brown MM. Patient Preference-Based Comparative Effectiveness and Cost-Utility Analysis of the Prostamides for Open-Angle Glaucoma. J Ocul Pharmacol Ther. 2019 04; 35(3):145-160.

View in: PubMed
Rabinowitz MP, Katz LJ, Moster MR, Myers JS, Pro MJ, Spaeth GL, Sharma P, Stefanyszyn MA. Unilateral Prostaglandin-Associated Periorbitopathy: A Syndrome Involving Upper Eyelid Retraction Distinguishable From the Aging Sunken Eyelid. Ophthalmic Plast Reconstr Surg. 2015 Sep-Oct; 31(5):373-8.

View in: PubMed
Shah M, Lee G, Lefebvre DR, Kronberg B, Loomis S, Brauner SC, Turalba A, Rhee DJ, Freitag SK, Pasquale LR. A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS One. 2013; 8(5):e61638.

View in: PubMed
Ichhpujani P, Katz LJ, Hollo G, Shields CL, Shields JA, Marr B, Eagle R, Alvim H, Wizov SS, Acheampong A, Chen J, Wheeler LA. Comparison of human ocular distribution of bimatoprost and latanoprost. J Ocul Pharmacol Ther. 2012 Apr; 28(2):134-45.

View in: PubMed
Faulkner R, Sharif NA, Orr S, Sall K, Dubiner H, Whitson JT, Moster M, Craven ER, Curtis M, Pailliotet C, Martens K, Dahlin D. Aqueous humor concentrations of bimatoprost free acid, bimatoprost and travoprost free acid in cataract surgical patients administered multiple topical ocular doses of LUMIGAN or TRAVATAN. J Ocul Pharmacol Ther. 2010 Apr; 26(2):147-56.

View in: PubMed
Ooi YH, Oh DJ, Rhee DJ. Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells. Invest Ophthalmol Vis Sci. 2009 Nov; 50(11):5259-65.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement